Antibodies, Fusion Proteins
Also Clin1 multiple cancers; INBRX-101 Clin1 alpha-1 antitrypsin deficiency (FT); INBRX-106 Clin1 multiple cancers; INBRX-105 Clin1 multiple cancers; INBRX-121 RD/Clin0 oncology
Inhibrx is a clinical-stage biotechnology company focused on helping people with life-threatening diseases. Using their protein-engineering expertise and proprietary single-domain antibody platform, Inhibrx has developed a unique and varied pipeline of novel therapeutic candidates. The platform enables the company to address complex target biology where other biologic approaches have previously failed as Inhibrix has the ability to create therapeutic candidates with defined valencies and specificities. Currently, Inhibrx has four programs all undergoing testing in clinical trials, three of which are for the treatment of cancer.
San Diego, CA|100+ days ago
Associate Director, Downstream Process Development...
San Diego, CA/ Hybrid|100+ days ago